Tallal Younis

790 total citations
34 papers, 577 citations indexed

About

Tallal Younis is a scholar working on Oncology, Cancer Research and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Tallal Younis has authored 34 papers receiving a total of 577 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 12 papers in Cancer Research and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Tallal Younis's work include Breast Cancer Treatment Studies (12 papers), HER2/EGFR in Cancer Research (10 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Tallal Younis is often cited by papers focused on Breast Cancer Treatment Studies (12 papers), HER2/EGFR in Cancer Research (10 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Tallal Younis collaborates with scholars based in Canada, United States and United Arab Emirates. Tallal Younis's co-authors include Daniel Rayson, Chris Skedgel, Penny J. Barnes, Kara Thompson, Nathalie Saint‐Jacques, Kiran Virik, Turki Alfayea, Gillian Bethune, Lynn Lethbridge and Kara Thompson and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Breast Cancer Research and Treatment.

In The Last Decade

Tallal Younis

31 papers receiving 566 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tallal Younis Canada 15 331 165 118 106 93 34 577
Catia Angiolini Italy 11 280 0.8× 104 0.6× 50 0.4× 84 0.8× 28 0.3× 20 570
G. Schubert-Fritschle Germany 16 485 1.5× 185 1.1× 217 1.8× 164 1.5× 40 0.4× 58 847
D Perrault Canada 11 382 1.2× 162 1.0× 120 1.0× 56 0.5× 34 0.4× 16 610
Joanna Dewar Australia 12 514 1.6× 228 1.4× 393 3.3× 117 1.1× 68 0.7× 23 970
Sandeep Sehdev Canada 13 272 0.8× 201 1.2× 122 1.0× 54 0.5× 31 0.3× 35 451
Katherine Enright Canada 10 412 1.2× 216 1.3× 138 1.2× 119 1.1× 31 0.3× 36 627
Z. Ballatore Italy 11 306 0.9× 174 1.1× 132 1.1× 94 0.9× 38 0.4× 35 544
Mei-Ching Liu Taiwan 11 323 1.0× 176 1.1× 127 1.1× 106 1.0× 41 0.4× 21 509
Victoria Neiman Israel 16 292 0.9× 141 0.9× 344 2.9× 178 1.7× 96 1.0× 58 615
Xiao-Ming Xie China 14 386 1.2× 260 1.6× 95 0.8× 90 0.8× 65 0.7× 22 629

Countries citing papers authored by Tallal Younis

Since Specialization
Citations

This map shows the geographic impact of Tallal Younis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tallal Younis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tallal Younis more than expected).

Fields of papers citing papers by Tallal Younis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tallal Younis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tallal Younis. The network helps show where Tallal Younis may publish in the future.

Co-authorship network of co-authors of Tallal Younis

This figure shows the co-authorship network connecting the top 25 collaborators of Tallal Younis. A scholar is included among the top collaborators of Tallal Younis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tallal Younis. Tallal Younis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Caissie, Amanda, et al.. (2024). Medical students' views on oncology specialty: A cross-sectional study.. Journal of Clinical Oncology. 42(16_suppl). 9038–9038.
2.
Yoo, Byong Hoon, Olivier Masson, Alexi P. Surette, et al.. (2018). ErbB2-driven downregulation of the transcription factor Irf6 in breast epithelial cells is required for their 3D growth. Breast Cancer Research. 20(1). 151–151. 11 indexed citations
3.
Younis, Tallal, et al.. (2016). Endocrine therapy for breast cancer prevention in high-risk women: clinical and economic considerations. Expert Review of Pharmacoeconomics & Outcomes Research. 16(2). 245–255. 3 indexed citations
4.
5.
Skedgel, Chris, Daniel Rayson, & Tallal Younis. (2015). Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?. Supportive Care in Cancer. 24(1). 387–394. 8 indexed citations
6.
Younis, Tallal, et al.. (2014). Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations. International Journal of Women s Health. 6. 509–509. 5 indexed citations
7.
8.
Skedgel, Chris, et al.. (2013). Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?. Expert Review of Pharmacoeconomics & Outcomes Research. 13(2). 243–250. 10 indexed citations
9.
Younis, Tallal, Daniel Rayson, & Kara Thompson. (2012). Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis. Supportive Care in Cancer. 20(10). 2523–2530. 39 indexed citations
10.
Younis, Tallal, et al.. (2012). Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations. Clinical Medicine Insights Oncology. 6. 179–87. 36 indexed citations
11.
Skedgel, Chris, et al.. (2012). Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer. Breast Cancer Research and Treatment. 133(3). 1115–1123. 49 indexed citations
12.
Snow, Stephanie, et al.. (2011). Routine Cardiac Evaluation in Patients With Early-Stage Breast Cancer Before Adjuvant Chemotherapy. Clinical Breast Cancer. 12(1). 4–9. 17 indexed citations
13.
14.
Younis, Tallal, et al.. (2009). Survivin and COX-2 expression in male breast carcinoma. The Breast. 18(4). 228–232. 11 indexed citations
15.
Skedgel, Chris, Daniel Rayson, & Tallal Younis. (2009). The Cost-Utility of Sequential Adjuvant Trastuzumab in Women with Her2/Neu-Positive Breast Cancer: An Analysis Based On Updated Results from the HERA Trial. Value in Health. 12(5). 641–648. 29 indexed citations
16.
Saint‐Jacques, Nathalie, et al.. (2008). Waiting Times in Early-Stage Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 3(8). 865–870. 32 indexed citations
17.
Younis, Tallal & Chris Skedgel. (2008). Is trastuzumab a cost-effective treatment for breast cancer?. Expert Review of Pharmacoeconomics & Outcomes Research. 8(5). 433–442. 10 indexed citations
18.
Younis, Tallal, et al.. (2008). Adjuvant Chemotherapy Uptake in Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 3(11). 1272–1278. 33 indexed citations
19.
Younis, Tallal, et al.. (2007). Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100. Breast Cancer Research and Treatment. 111(2). 261–267. 22 indexed citations
20.
Ling, Xiang, Jie Yang, Nithya Ramnath, et al.. (2005). Differential expression of survivin-2B and survivin-ΔEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC). Lung Cancer. 49(3). 353–361. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Catia Angiolini Breakdown of academic impact, for papers by G. Schubert-Fritschle Breakdown of academic impact, for papers by D Perrault Breakdown of academic impact, for papers by Joanna Dewar Breakdown of academic impact, for papers by Sandeep Sehdev Breakdown of academic impact, for papers by Katherine Enright Breakdown of academic impact, for papers by Z. Ballatore Breakdown of academic impact, for papers by Mei-Ching Liu Breakdown of academic impact, for papers by Victoria Neiman Breakdown of academic impact, for papers by Xiao-Ming Xie
Rankless by CCL
2026